Alcon, Novartis’ ophthalmic division, has gained exclusive ex-US rights to commercialise ThromboGenics’ ocriplasmin for symptomatic vitreomacular adhesion in a deal potentially worth more than €375 M (US$489 M), including €75 M (US$98 M) upfront. Ocriplasmin is under regulatory review by the EMA and Alcon, the leading player in the global ophthalmology market, plans to market the drug in more than 40 countries worldwide.